🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A great chance to work with star scientist @tudballstats

If you are attending #ASHG23 and are interested in new biomarkers for childhood cardiometabolic disorders check out our posters at Complex Traits and Polygenic Disorders Poster Sessions I & II

After a frustrating hour attempting chasing citation chains ending in non-existent primary sources, I turn to the wisdom of the internet: what is the most robust primary source for an estimate of the aggregate incidence of rare genetic diseases?

Really excited to announce the successful completion of Satoshi Yoshiji's PhD in Human Genetics at McGill!! Congrats on passing at top 10% with no revisions. Satoshi joined our team about 18 months ago and has already been recruited to faculty at McGill :-)

I just learned from Eric Fauman (he/him) that the first GWAS ever in the GWAS catalog was from Fernando Rivadeneira @minouye271 Nicole Soranzo Tim Spector MD (Prof) and me. Couldn't have imagined the treasure trove that would spring from that catalog in 2008... linkedin.com/pulse/seven-da…

Exciting Parkinson's disease GWAS in NG. While eQTL MR can sometimes be helpful, eQTLs from GTEx are not enriched for disease heritability. If the eQTLs don't harbour heritable signals, what do the MR results mean? nature.com/articles/s4158…

Drug development programs with support from human genetics are 2-3 fold more successful. 3 take-aways: 1. Effect size of genetic association doesn't matter. 2. Indications with biomarkers are more successful 3. Less helpful for symptoms of disease. nature.com/articles/s4158…

David Grainger These statements are strange and false. 1. Statins' target HMGCoA has overwhelming genetic support. 2. How could a vaccine have human genetic support? 3. GLP1R has variants associated with CAD, fasting glucose and T2D 4. Mutations in the target of Plavix cause bleeding disorders

GWAS findings for a drug target more than double the likelihood of FDA approvals. But most often, it is difficult to understand the causal gene at a GWAS locus. At 5 Prime Sciences , we've developed PRIMEx, a machine learning algorithm to prioritize genes from GWAS loci,

As the CEO of 5 Prime Sciences, I'm very excited to announce a multi-year strategic partnership with Eli Lilly and Company to identify and validate drug targets for cardio-metabolic diseases. 5primesciences.com/news/

Kudos brent richards 👏👏👏 Great to see that 5 Prime Sciences is advancing and to see this multi-year partnership with Eli Lilly and Company

Terrific partnership announced between Eli Lilly and Company and 5 Prime Sciences. Congrats brent richards and team for the progress on developing advanced -omics capabilities for target validation, an often under-appreciated gap in drug discovery and development

Super happy that this project is finally published. Big thanks to the BQC19 collaboration at McGill and University of Montreal as well as the group in Chicago. link.springer.com/article/10.103… Dr. Amanda Marks brent richards

Interesting use of ChatGPT to predict causal genes at GWAS loci. Obviously biased towards genes of known biology (which does not mean that they are more likely to be causal, since most published literature is false). medrxiv.org/content/10.110…

Thrilled to see Lipigon Pharmaceuticals dose the first patient in their Phase II trial for Lipisense®. 5 Prime Sciences is proud to have supported Lipigon by validating their target, ANGPTL4. 🔗 Learn more here: lnkd.in/eHQhidqR and 5primesciences.com/news/